Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NRXP | Common Stock | Purchase | $285K | +288K | $0.99 | 288K | Nov 16, 2022 | Direct | F1 | |
transaction | NRXP | Common Stock | Purchase | $186K | +172K | +59.68% | $1.08 | 460K | Nov 17, 2022 | Direct | F2 |
transaction | NRXP | Common Stock | Purchase | $44.4K | +40.4K | +8.79% | $1.10 | 500K | Nov 18, 2022 | Direct | F3 |
holding | NRXP | Common Stock | 1.44M | Oct 21, 2022 | By Shirat HaChaim Ltd. | ||||||
holding | NRXP | Common Stock | 208K | Oct 21, 2022 | By CH Health-Private Venture Capital Ltd. |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | NRXP | Employee Stock Option | Award | +163K | +74.47% | 381K | Oct 21, 2022 | Common Stock | 163K | $0.75 | Direct | F4 |
Id | Content |
---|---|
F1 | The price reported above reflects the weighted average purchase price per share of common stock (the "Common Stock"), of NRx Pharmaceuticals, Inc. (the "Issuer"). The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. |
F2 | The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. |
F3 | The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common |
F4 | Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer. |